Terms: = Ovarian cancer AND JUN, P05412, 3725, ENSG00000177606, AP1, c-Jun
345 results:
1. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.
Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A
J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587
[TBL] [Abstract] [Full Text] [Related]
2. SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation.
Gong TT; Liu FH; Xiao Q; Li YZ; Wei YF; Xu HL; Cao F; Sun ML; Jiang FL; Tao T; Ma QP; Qin X; Song Y; Gao S; Wu L; Zhao YH; Huang DH; Wu QJ
Commun Biol; 2024 Jan; 7(1):67. PubMed ID: 38195842
[TBL] [Abstract] [Full Text] [Related]
3. Exploration of the effect and mechanism of Scutellaria barbata D. Don in the treatment of ovarian cancer based on network pharmacology and in vitro experimental verification.
Zhang J; Qi C; Li H; Ding C; Wang L; Wu H; Dai W; Wang C
Medicine (Baltimore); 2023 Dec; 102(51):e36656. PubMed ID: 38134066
[TBL] [Abstract] [Full Text] [Related]
4. Oxfendazole Induces Apoptosis in ovarian cancer Cells by Activating JNK/MAPK Pathway and Inducing Reactive Oxygen Species Generation.
Chen Y; Wen C; Zhong S; Huang L; Xiang Y; Ou Y; Li L; Tang W; Zhou C; Wu Z; Ye W; Wu S; Huang S; Li Z
Biol Pharm Bull; 2023; 46(11):1569-1575. PubMed ID: 37914359
[TBL] [Abstract] [Full Text] [Related]
5. The Network Pharmacology Analysis of Tonifying Yang Formula for the Treatment of Diminished ovarian Reserve.
Ma Q; Wu X; Chen D; Li W; Wu J; Shen M; Ye C; Tan Y; Guo Q
Altern Ther Health Med; 2024 Mar; 30(3):176-184. PubMed ID: 37883761
[TBL] [Abstract] [Full Text] [Related]
6. Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas.
Machino H; Dozen A; Konaka M; Komatsu M; Nakamura K; Ikawa N; Shozu K; Asada K; Kaneko S; Yoshida H; Kato T; Nakayama K; Saloura V; Kyo S; Hamamoto R
Exp Mol Med; 2023 Oct; 55(10):2205-2219. PubMed ID: 37779141
[TBL] [Abstract] [Full Text] [Related]
7. EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-jun signaling to promote the invasion of ovarian cancer cells.
Shen X; Jin X; Fang S; Chen J
Cell Mol Biol Lett; 2023 Jul; 28(1):53. PubMed ID: 37420173
[TBL] [Abstract] [Full Text] [Related]
8. MKK4 Inhibitors-Recent Development Status and Therapeutic Potential.
Katzengruber L; Sander P; Laufer S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108658
[TBL] [Abstract] [Full Text] [Related]
9. The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China.
Zhou S; Song B; Li C; Tang W; Zhang X; Jin X; Xu X; Wang Q; Zheng H; Fu J
Sci Rep; 2023 Feb; 13(1):3185. PubMed ID: 36823199
[TBL] [Abstract] [Full Text] [Related]
10. Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in ovarian cancer Cells.
Rabelo-Fernández RJ; Noriega Rivera RA; Rivera YS; Tous-Beveraggi J; Valiyeva F; Vivas-Mejia PE
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499073
[TBL] [Abstract] [Full Text] [Related]
11. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in ovarian cancer.
McMellen A; Yamamoto TM; Qamar L; Sanders BE; Nguyen LL; Ortiz Chavez D; Bapat J; Berning A; Post MD; Johnson J; Behbakht K; Nurmemmedov E; Chuong EB; Bitler BG
Mol Cancer Res; 2023 Jan; 21(1):3-13. PubMed ID: 36149636
[TBL] [Abstract] [Full Text] [Related]
12. Phosphorylation of mixed lineage kinase MLK3 by cyclin-dependent kinases CDK1 and CDK2 controls ovarian cancer cell division.
Cedeno-Rosario L; Honda D; Sunderland AM; Lewandowski MD; Taylor WR; Chadee DN
J Biol Chem; 2022 Aug; 298(8):102263. PubMed ID: 35843311
[TBL] [Abstract] [Full Text] [Related]
13. Expression and purification of recombinant human CCL5 and its biological characterization.
Ma Z; Zhang J; Wang L; Liu Y; Wang Y; Liu W; Xing G; Cheng K; Zheng W; Xiang L
Protein J; 2022 Apr; 41(2):337-344. PubMed ID: 35524873
[TBL] [Abstract] [Full Text] [Related]
14. Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer.
Sestito R; Tocci P; Roman C; Di Castro V; Bagnato A
J Exp Clin Cancer Res; 2022 Apr; 41(1):157. PubMed ID: 35477522
[TBL] [Abstract] [Full Text] [Related]
15. Preclinical
Li Y; Chen Y; Wei M; Wei C
Front Endocrinol (Lausanne); 2022; 13():845404. PubMed ID: 35464051
[TBL] [Abstract] [Full Text] [Related]
16. Nap1L1 promotes tumor proliferation through HDGF/C-jun signaling in ovarian cancer.
Xiaohua Zhu ; Xie Y; Huang W; Chen Z; Guo S
BMC Cancer; 2022 Mar; 22(1):339. PubMed ID: 35351053
[TBL] [Abstract] [Full Text] [Related]
17. Glaucocalyxin B Attenuates ovarian cancer Cell Growth and Cisplatin Resistance In Vitro via Activating Oxidative Stress.
Zhang T; Xu C; Zheng P; Zhang X; Qiu C; Wu F; Chen J; Xiao Z; Zhu J; Zhang J; Zou P; Ni D
Oxid Med Cell Longev; 2022; 2022():6324292. PubMed ID: 35251480
[TBL] [Abstract] [Full Text] [Related]
18. The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.
Machino H; Kaneko S; Komatsu M; Ikawa N; Asada K; Nakato R; Shozu K; Dozen A; Sone K; Yoshida H; Kato T; Oda K; Osuga Y; Fujii T; von Keudell G; Saloura V; Hamamoto R
Commun Biol; 2022 Jan; 5(1):39. PubMed ID: 35017636
[TBL] [Abstract] [Full Text] [Related]
19. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in ovarian cancer Cells.
Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in ovarian cancer.
Javellana M; Eckert MA; Heide J; Zawieracz K; Weigert M; Ashley S; Stock E; Chapel D; Huang L; Yamada SD; Ahmed AA; Lastra RR; Chen M; Lengyel E
Cancer Res; 2022 Jan; 82(1):169-176. PubMed ID: 34737212
[TBL] [Abstract] [Full Text] [Related]
[Next]
